6:20 PM
 | 
Dec 06, 2012
 |  BC Extra  |  Company News

EMA to review PTC's ataluren

PTC Therapeutics Inc. (South Plainfield, N.J.) said EMA accepted for review an MAA seeking conditional approval of ataluren to treat nonsense mutation Duchenne muscular dystrophy (DMD)....

Read the full 113 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >